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Xenografting pig fetal ventral mesencephalic (pfVM) cells to repair the dopamine deficit in patients with
Parkinson’s disease is the focus of both experimental and clinical investigations. Although there have been
marked advances in the experimental and even clinical application of these xenogeneic transplantations,
questions regarding the host’s xenospecific immune response remain unanswered. It has been shown that
human serum is able to lyse pfVM tissue by both anti-gal-gal and non-anti-gal-gal antibodies by complement
activation. The aim of this study was to investigate whether interindividual differences exist in the levels of
pfVM cell-specific IgM and IgG subclass antibodies, their ability to lyse pfVM cells in vitro and the relation-
ship between both. Pig fetal VM cells were incubated with heat-inactivated serum from 10 different individu-
als and binding of IgM antibodies and IgG subclass antibodies to pfVM cells was analyzed by flow cytome-
try. The ability to lyse pfVM cells was analyzed exposing 51Cr-labeled pfVM cells to fresh serum or isolated
IgM and IgG from the same individuals and subsequent determination of released 51Cr from lysed cells.
Strong differences were found between individuals in the levels of pfVM cell-specific IgM antibodies: anti-
body levels differed up to 40-fold. pfVM-specific IgG1 and IgG2 levels were only detectable in a few
individuals. The ability to lyse pfVM cells ranged from negligible lysis up to 66.5% specific lysis. There
was a strong correlation between the levels of individual pfVM-specific IgM antibodies and the ability to
lyse pfVM cells in vitro. Isolated IgM, but not IgG, was able to lyse pfVM cells in the presence of comple-
ment. In conclusion, the interindividual differences in the levels of IgM with affinity for pfVM cells and
their ability to lyse pfVM cells in vitro are considerable. Only few individuals possessed IgG1 and IgG2
subclass antibodies with affinity for pfVM. These findings may influence patient selection for porcine trans-
plants and chances of graft survival in individual patients.
Key words: Xenotransplantation; Ventral mesencephalon; Parkinson’s disease;
Complement-dependent cytotoxicity; Porcine
INTRODUCTION practical, ethical, and possibly infectious difficulties as-
sociated with its use (5,10–13,17,18,23). There have
Cellular transplantation to repair the dopamine deficit been marked advances in the experimental and even
in patients with Parkinson’s disease using fetal dopa- clinical application of these xenogeneic transplantations
menergic tissue has been the focus of both experimen- (4,6). However, many questions remain unanswered, es-
tal and clinical investigations for over three decades pecially those regarding the host’s immune response and
(3,7–9,19,24). The possible usage of pig fetal ventral in particular the role of xenospecific “natural antibodies”
mesencephalic (pfVM) tissue as a donor source has been against an intracerebral xenogeneic implant.
investigated to overcome the limited availability of abor- Human serum is toxic to pig cells but different hu-
tion-derived human fetal dopaminergic tissue as well as man individuals show considerable quantitative differ-
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ences in their ability to lyse adult, nonneural porcine tion of 0.5 mg/ml IgM and 4 mg/ml IgG to avoid influ-
ence of individual antibody levels.tissue by complement activation (21). Toxicity to pfVM
tissue has been demonstrated for pooled human serum
and was found to be mediated not only by anti-gal-gal Determination of Cytotoxicity
antibodies but also by non-anti-gal-gal antibodies (22).
The ability of sera to lyse pfVM cells was analyzedThe aims of this study were to investigate: 1) whether
by exposing 51Cr-labeled pfVM cells to fresh serum andinterindividual differences exist in the ability to specifi-
subsequent determination of released 51Cr from lysedcally lyse pfVM cells in vitro, 2) the serum levels of
cells. To label pfVM cells with 51Cr approximately 20pfVM cell-specific IgM and IgG subclass antibodies,
million cells were incubated with 51Cr (200 µCi) in 100and 3) the relationship between the toxicity of sera to
µl PBS for 60 min at 37°C. Cells were subsequentlypfVM and serum levels of pfVM cell-specific IgM and
washed with AIM-V medium and albumin (9:1) threeIgG.
times before being centrifuged for 5 min at 1800 rpm
and resuspended in 1 ml AIM-V. The suspension wasMATERIALS AND METHODS
diluted to 5 × 104 cells/ml and plated at 100 µl/well in aAntibodies and Reagents 96-well plate (Costar). Next, 100 µl/well of prediluted
Affinity chromatography used anti-human IgM agar- serum, IgM/IgG subfractions, and/or rabbit complement
ose (Sigma, A9935) and MabTrap GII kit (Pharmacia was added at twofold dilutions. Alternatively, fresh hu-
Biotech, 17-1128-01). Complements were Cedarlane CL3335 man serum deficient of pfVM-specific IgM and IgG was
Low-tox-H rabbit complement and Biotest 824050 used as a complement source. Maximum 51Cr release
Complement. The medium used was AIM-V Gibco. was determined adding Triton X-100 and background
Fluorescent antibodies used were goat anti-human-IgM- release adding AIM-V. After 60 min at 37°C the super-
FITC (Protos) dilution 1:40; mouse anti-human-IgG1- natant was removed and released 51Cr was measured us-
FITC (Zymed) dilution 1:20; mouse anti-human-IgG2- ing a Packard gamma counter. The percentage specific
FITC (Zymed) dilution 1:20; mouse anti-human-IgG3-FITC lysis was calculated as the measured minus background
(Zymed) dilution 1:20; mouse anti-human-IgG4-FITC (Zy- release divided by the difference between maximum and
med) dilution 1:20; and mouse anti-human-IgG-FITC background release. All measurements were performed
(Sigma) dilution 1:10. in triplets and data are expressed as mean values.
Isolation and Preparation of Fetal VM Tissue Binding of Antibodies to pfVM
Porcine fetuses were obtained from anesthetized 28-
To investigate the binding of different human immu-day pregnant cross-bred Dutch Yorkshire Landrace pigs
noglobulin classes and subclasses to pfVM cells, cellsby hysterotomy and the VM was immediately micro-
were incubated with heat-inactivated serum from 10 dif-
scopically dissected as previously described (11,17,23).
ferent individuals. Binding of IgM antibodies and IgGThe VM was then cut into six to eight small pieces and
subclass antibodies was analyzed by flow cytometry.
stored in saline for 2 h at 4°C before being processed
More specifically, cells were incubated with serum forinto a single cell suspension (14). Viability was assessed
30 min at 37°C and subsequently washed three times
using the trypan dye exclusion test and viability was ex-
with HBSS. Next, the cells were incubated for 30 minpressed as percentage of viable cells with respect to the
at 4°C with Ig class or subclass-specific fluorescent anti-total number of cells.
bodies. Cells were subsequently washed twice with HBSS
and analyzed on a flow cytometer (Coulter Epics Elite).Human Serum and Immunoglobulin Purification
To allow comparison of individual sera, measurements
Human serum was obtained from 10 healthy volun- were done in one run with fixed settings of the flow
teers. None of the individuals was ever directly exposed cytometer. Binding of pfVM-specific antibodies was ex-
to porcine antigens (i.e., porcine insulin) or worked on pressed as the percentage of positive cells. Five percent
a pig farm. All individuals ate (pig) meat. The serum or more positive cells was considered confident evi-
was either used fresh or heat inactivated and stored at dence for the presence of pfVM-specific antibodies.
−20°C until later use. Purified IgM and IgG was ob-
tained from the sera by affinity chromatography using
Statistics
anti-human IgM agarose and MabTrap GII kit following
the manufacturer’s instructions. The concentration of the Statistical analyses were performed using GraphPad
Prism version 3.00 for Windows (GraphPad Software,purified IgM and IgG in the individual solutions after
purification was determined using the Dade Behring San Diego, CA). A Spearman test was performed to cal-
culate correlation.BN2 and subsequently diluted to a standard concentra-
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Figure 1. Binding of IgM and IgG subclass antibodies to pfVM as analyzed by flow cytometry and expressed as percentage of
positive cells. All measurements for different antibodies were performed in one run with fixed settings of the flow cytometer to
allow comparison of 10 individual sera. Five percent or more positive cells was considered confident evidence for the presence of
pfVM-specific antibodies.
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RESULTS
Individual Differences in Human
pfVM-Specific Antibodies
Interestingly, strong differences were found between
individuals in the levels of mainly IgM class pfVM cell-
specific antibodies as was indicated by flow cytometry
analysis of binding of human antibodies to pfVM: anti-
body levels differed up to 40-fold. All but one sera con-
tained pfVM cell-specific IgM antibodies, while two
sera additionally contained small amounts of pfVM cell-
specific IgG2 subclass antibodies (sera 1 and 9) and
three sera contained pfVM-specific IgG1 subclass anti-
bodies (sera 1, 5, and 9) (Fig. 1).
Individual Serum Levels of pfVM-Specific IgM
Correlates With Ability to Lyse pfVM
The ability to lyse pfVM cells was present in almost Figure 3. Correlation between the amount of pfVM-specific
all sera, but large interindividual differences were found. IgM and cytotoxicity of 10 respective human sera (data from
The ability to lyse pfVM cells ranged from negligible Figs. 1 and 2). Using Spearman correlation: r = 0.93 and p =
0.0002, indicating a strong correlation between individual se-lysis up to 66.5% specific lysis (1:4 dilution of the se-
rum levels of pfVM-specific IgM antibodies and the ability torum) (Fig. 2).
lyse pfVM cells in vitro.There was a strong correlation between individual se-
rum levels of pfVM-specific IgM antibodies and the
ability to lyse pfVM cells in vitro (r = 0.93, p = 0.0002, cific lysis (1:4 dilution) was found (Fig. 4). Heat-inacti-
Spearman correlation) (Fig. 3). vated rabbit serum did not kill pfVM cells (Fig. 4). As
an alternative to rabbit complement we used serum from
Rabbit Serum as a Complement Source donor 3 as a complement source (Fig. 4).
Toxic to pfVM Cells
Isolated IgM and Not IgG Toxic to pfVM CellsIn our experiments testing isolated IgM and IgG from
in the Presence of Complementdifferent donors for cytotoxicity using rabbit serum as a
complement source, we found that rabbit serum from The ability of isolated IgM from different individuals
to lyse pfVM cells showed marked individual differ-different sources is toxic to pfVM cells. Up to 63% spe-
Figure 2. Cytotoxicity of 10 individual fresh sera to pfVM cells analyzed in a 51Cr release assay
and expressed as the percentage specific lysis. For each individual serum cytotoxicity of serum (in
4 twofold dilutional steps) was determined. All measurements were performed in triplet. Data are
expressed as mean values.
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Figure 4. Cytotoxicity of fresh and heat-inactivated rabbit complement as well as fresh and de-
complemented serum of individuals 1 and 3. Individual 1 demonstrated high level of pfVM-
specific IgM level and toxicity to pfVM, whereas individual 3 demonstrated no detectable level of
pfVM-specific IgM and was not toxic to pfVM cells (data from Figs. 1 and 2). To test whether
individual 3 could serve as a complement source, decomplemented serum from individual 1 (“high
IgM”) was mixed with fresh serum from individual 3 (“low IgM”). Data show that the rabbit
complement we used is toxic to pfVM cells and that this toxicity is complement dependent because
heat-inactivated serum does not kill pfVM cells. Mixing heat-inactivated serum from individual 1
(in itself nontoxic to pfVM) with fresh serum from individual 3 (nontoxic to pfVM cells), 63%
specific lysis was measured, decreasing with further dilution of serum from individual 1. Based
on these data we used individual 3 as an alternative complement source for further experiments
with either isolated IgM or IgG.
ences as observed with fresh serum, ranging between lysis of donor cells by complement activation. Sumitran
et al. demonstrated that pooled human AB serum con-not detectable and 24.1% specific lysis (Fig. 5A). There
was a strong correlation between fresh serum and iso- tains IgG and IgM antibodies directed against galα1,3-
gal as well as non-gal epitopes on pfVM tissue, and thatlated IgM in the ability to lyse pfVM cells in vitro (r =
0.68, p = 0.347, Spearman correlation). However, isolated human serum as well as human serum depleted of α-gal
antibodies is able to lyse pfVM cells by complementIgM showed a decrease in the percentage of specific lysis
compared with fresh serum. The ability of isolated IgG activation (22). In their studies they showed that both
isolated IgG and IgM are cytotoxic to pfVM cells in theto lyse pfVM cells never exceeded 5.8% specific lysis
and should be considered negative (Fig. 5B). presence of complement (22). In contrast, we could not
demonstrate cytotoxicity of isolated IgG to pfVM.
DISCUSSION Pooled serum as was used by Sumitran et al. perhaps
contains serum from an individual with high IgG levelsOur results show that most human serum is able to
lyse pig fetal ventral mesencephalic cells by way of with affinity for pfVM. We do not think that our results
are influenced by the use of fresh serum from a donorcomplement activation. There are however large differ-
ences in the extent to which these sera are able to lyse without IgM with affinity for pfVM instead of rabbit
complement, although it cannot be excluded.pfVM cells. In the sera used for this study, specific lysis
of pfVM ranged from negligible lysis up to 66.5% at Differences between human sera in their toxicity to
pfVM are significant. In our study, lysis of pfVM cells1:4 serum dilutions. There was a strong correlation be-
tween the amount of IgM class antibodies with affinity by human serum differed from 0 to 66.5% specific lysis.
Schaapherder et al. tested a large series of different hu-for pfVM and the ability to lyse pfVM in the respective
sera. We found only very low levels of IgG subclass man donors and found substantial interindividual differ-
ences in both toxicity against nonneural tissue [porcineantibodies with affinity for pfVM in a minority of do-
nors, and were not able to show IgG-induced lysis of endothelial cells (PEC) and porcine islet cells (PIC)]
(61% specific lysis average, range 38–81%; n = 30) andpfVM by complement activation.
Xenoreactive antibodies have been shown to cause the amount of antibodies directed against nonneural por-
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Figure 5. Cytotoxicity of isolated IgM (concentration 0.5, 0.25, 0.125 and 0.06 mg/ml) (A) and
isolated IgG (concentration 4, 2, 1, and 0.5 mg/ml) (B) from 10 individuals, expressed as the
percentage specific lysis of pfVM cells, using fresh serum from individual 3 as a complement
source. All measurements were performed in triplet and data expressed as mean values. Isolated
IgM, like fresh serum, shows large individual differences in the ability to lyse pfVM cells whereas
isolated IgG shows no detectable lysis.
cine cells (20,21). Importantly, they demonstrated that In vivo studies have shown that there may be an im-
portant role for antibodies and complement in the re-agammaglobulinemic sera killed approximately 42% of
PIC (21), suggesting complement activation via the al- jection of an intracerebral xenograft, both indirectly by
facilitating a cellular response, and directly via comple-ternative pathway. In contrast, we found no indication
of the latter, as serum without IgM directed against ment activation and subsequent cell death (1,2,15,16).
Acknowledging these findings, our data, showing con-pfVM gave no detectable lysis of pfVM. Further, there
was a strong correlation between the individual serum siderable differences between different human individu-
als in levels of (primarily) IgM class antibodies directedlevels of pfVM-specific IgM antibodies and the ability
to lyse pfVM cells in vitro, suggesting complement ac- against pfVM cells and their ability to lyse pfVM cells
via complement activation, can in our opinion have clin-tivation via the classical pathway. This may indicate
that transplantation of neural tissue is safe with respect ical significance in terms of patient selection for porcine
transplants and chances of graft survival in individualto activation via the alternative complement activation
pathway. patients.
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